The targeted therapy onalespib has shown effectiveness in preclinical studies of glioblastoma by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James). Onalespib is designed to inhibit a molecule called HSP90. The molecule helps newly made protein molecules fold into...